Fiche publication
Date publication
août 2025
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
,
Pr LEPAGE Côme
Tous les auteurs :
Tougeron D, Mineur L, Zaanan A, Kadi M, Poisson Ligeza C, Bourgeois V, Martin-Babau J, Fadin A, Jestin le Tallec V, Ly Lebrun V, Dubreuil O, Khemissa Akouz F, Thimonier E, Bouché O, Lièvre A, Di Fiore F, Lecomte T, Lepage C, Hautefeuille V,
Lien Pubmed
Résumé
Metastatic esophageal squamous cell carcinoma (mESCC) patients with disease progression after platinum-based first-line chemotherapy (CT) +/- immune checkpoint inhibitors (ICI) may benefit from second-line CT, mostly based on paclitaxel and irinotecan, but no randomized trial has compared these regimens.
Mots clés
Esophageal cancer, Irinotecan, Paclitaxel, Squamous cell carcinoma
Référence
Eur J Cancer. 2025 08 22;228:115741
